ArticlePloS one2019
Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee.European heart journal. Cardiovascular pharmacotherapy · 2025Guideline
- Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors-A Systematic Review.Basic & clinical pharmacology & toxicology · 2025Pooled it
- [Consensus recommendations on the diagnosis and treatment of hyperkalemia of the Austrian Society of Nephrology 2026].Wiener klinische Wochenschrift · 2026Review
- The burden of hyperkalaemia in chronic kidney disease: a systematic literature review.Clinical kidney journal · 2025Article
- Consequences of Recurrent Hyperkalemia on Cardiovascular Outcomes and Mortality.JACC. Advances · 2024Article
- Management of hyperkalemia: Expert consensus from Kuwait - a Modified Delphi Approach.International journal of nephrology and renovascular disease · 2024Article
- Liver Disease Is a Risk Factor for Recurrent Hyperkalemia: A Retrospective Cohort Study.Journal of clinical medicine · 2023Article
- Trimethoprim-sulfamethoxazole and the risk of a hospital encounter with hyperkalemia: a matched population-based cohort study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Hyperkalemia: Prevalence, Predictors and Emerging Treatments.Cardiology and therapy · 2023Review
- Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.BMC nephrology · 2023Observational
- Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care.Canadian journal of kidney health and disease · 2023Review
- Article
- Impact of chronic potassium binder treatment on the clinical outcomes in patients with hyperkalemia: Results of a nationwide hospital-based cohort study.Frontiers in physiology · 2023Article
- Chronic hyperkalemia, diagnosis and management. Colombian consensus.Archivos de cardiologia de Mexico · 2023Article
- Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy.Current heart failure reports · 2022Review
- Predictors of Hyperkalemia among Patients on Maintenance Hemodialysis Transported to the Emergency Department by Ambulance.Kidney360 · 2022Article
- The Impact of Hyperkalemia on Mortality and Healthcare Resource Utilization Among Patients With Chronic Kidney Disease: A Matched Cohort Study in China.Frontiers in public health · 2022Article
- Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease.Clinical kidney journal · 2022Article
- Course of Hyperkalemia in Patients on Hemodialysis.International journal of nephrology · 2022Article
- Prevention and management of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding predictors and trajectories of increased potassium may inform testing and treatment of hyperkalemia. We examined predictors for repeated hyperkalemia among patients after first-time renin angiotensin system inhibitor (RASi) prescription, chronic kidney disease (CKD), or chronic heart failure (CHF); and we also examined potassium trajectories in these patients after their first hyperkalemia event. We used Danish population-based registries to identify all patients with first-time RASi prescription, incident CKD, or incident CHF (2000-2012). For patients with a first hyperkalemia event, potassium trajectories over the following 6 months were examined. The predictors associated with repeated hyperkalemia were assessed, with repeated hyperkalemia defined as a potassium test >5.0 mmol/L after the first event within 6 months. Overall 262,375 first-time RASi users, 157,283 incident CKD patients, and 14,600 incident CHF patients were included. Of patients with a first hyperkalemia event, repeated hyperkalemia within 6 months occurred in 37% of RASi users, 40% with CKD, and 49% of patients with CHF. Predictors included severe hyperkalemia, low eGFR, diabetes, and spironolactone use. In all cohorts, the median potassium levels declined over 2-4 weeks after a hyperkalemia event for the first time, but reverted to levels higher than before the initial hyperkalemia event in those who had repeated hyperkalemia. Following hyperkalemia, discontinuation of RASi and spironolactone was common in the RASi and CHF cohorts. Repeated hyperkalemia was common among the explored cohorts. The first hyperkalemia event was an indicator of increased median potassium levels. Predictors may identify patients likely to benefit from intensified monitoring and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.